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https://doi.org/10.1016/j.trsl.2019.0Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that
results from b-cell destruction. The onset of the disease, which arises after a long
asymptomatic period of autoimmune attack, may be followed by a relapsing and
remitting progression, a phenomenon that is most evident during the partial remis-
sion phase (PR). This stage lasts for a fewmonths, shows minor requirements of exog-
enous insulin and could be explained by a recovery of immunological tolerance.
This study aims to identify new biomarkers at early stages of pediatric T1D that
reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52)
and age-related control subjects (n = 30) were recruited. Immune response-related
molecules and lymphocyte subsets were determined starting at T1D onset and until
the second year of progression. Results showed that circulating TGF-b levels
decreased during PR, and that betatrophin concentration was increased in all the
considered stages without differing among studied checkpoints. Moreover, an
increase of regulatory T, B and NK subsets was found during T1D progression, proba-
bly reflecting an attempt to restore self-tolerance. By contrast, a reduction in mono-
cyte levels was observed at the early stages of diabetes. The results reveal
significant changes in immunological parameters during the different early stages
of T1D in children, which could ultimately serve as potential biomarkers to charac-
terize the progression of T1D. (Translational Research 2019; 210:825)Abbreviations: aTreg = activated regulatory T; BLMS = B lymphocyte maturation stages;
BMI = body mass index; Breg = regulatory B; CM = central memory; DP = double-positive;mans Trias i Pujol Research Institute, Badalona, Spain; Pediatrics Section, Germans Trias i Pujol Research Insti-
onomous University of Barcelona, Badalona, Spain; CIBER of Diabetes and Associated Metabolic Disease
pain.
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Volume 210 Villalba et al 9EM = effector memory; HbA1c = glycated hemoglobin; IDDAA1c = insulin dose-adjusted
HbA1c; mTreg = memory regulatory T; NKreg = regulatory Natural Killer; PR = partial remission;
PBMCs = peripheral bloodmononuclear cells; Treg = regulatory T; TLMS = T lymphocyte matura-
tion stages; T1D = type 1 diabetesAT A GLANCE COMMENTARY
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Background
This study provides new candidate biomarkers 
betatrophin, TGF-b, and regulatory T, B and NK
subsets  that reflect the immunoregulatory
attempts during early progression of pediatric
type 1 diabetes, including partial remission stage.
Translational Significance
These findings suggest that regulatory lympho-
cytes as well as betatrophin and TGF-b molecules
may be related to partial remission and progres-
sion of type 1 diabetes in children. Moreover, and
because partial remission may be a good stage for
immunointervention, these candidate biomarkers
can be considered for clinical trials.INTRODUCTION
Type 1 diabetes (T1D) is a metabolic disease
caused by the autoimmune destruction of insulin-pro-
ducing b-cells. After the clinical onset, and probably
due to the beginning of insulin therapy, between 50%
and 80% of pediatric patients with T1D undergo a
partial remission (PR) phase, also known as honey-
moon, starting at 6 months of disease progression and
lasting up to 2 years.1 This transient period is defined
by low requirements of insulin and diminished gly-
cated hemoglobin2,3 (HbA1c) and could be an optimal
phase for immune intervention and other therapeutic
strategies. Clinical trials using immunotherapies have
failed to provide long-term b-cell protection, partly
due to the stage chosen for immunointervention.4
Hence, it is necessary to identify new biomarkers
which will enable the monitoring of the PR and the
early stages of T1D.
A reliable biomarker has to be robust and allow for
the distinction of control and patients, or in this case,
patients at different stages of disease. For T1D, it
should fulfil several requirements4: (1) To reflect the
variations of the autoimmune response or b-cell regen-
eration5; (2) To be easy to obtain with minimum dis-
comfort or risk for the patient; (3) To display
variations over the progression of the disease; (4) To
allow the monitoring of the patient’s response to
immunotherapies; (5) To have available a sensitive,specific, and highly reproducible detection method. At
present, most used biomarkers in T1D are metabolic
(HbA1c and C-peptide), but they do not reflect the
pathophisiology of T1D. HbA1c is strongly dependent
on daily glycemia and C-peptide levels are usually not
detectable after the clinical onset.6 Autoantibodies
against b-cell antigens are immunological biomarkers
for T1D but they do not always predict the develop-
ment of the disease or the severity of secondary com-
plications. Specific autoreactive T cells were also
proposed as biomarkers but the reproducibility of
experiments involving antigen-specific T cells has
been questioned.7
Several candidate biomarker have arised in the last
years. Betatrophin is one of these candidates, since
its circulating levels in plasma were found increased
in adult patients with long-standing T1D.8 Another
candidate was TGF-b, due to its role in immunoregu-
lation and the alterations found in the pancreases
from patients.9 Moreover, plasma levels of TGF-b
are increased in adult patients at the onset, indicating
that TGF-b plays a role in chronic inflammation in
T1D.10 Other candidates are molecules with altered
expression in the pancreases from patients at differ-
ent disease stages,11 and circulating leukocyte sub-
sets,12,13 that can be easily obtained from peripheral
blood of pediatric subjects and be identified with a
high resolution in an automated manner.14 Our study
aims at unravelling for the first time the characteriza-
tion of the changes in these markers/subsets during
the early stages of pediatric T1D.MATERIAL AND METHODS
Participants. Pediatric patients with T1D (n = 52)
and age-related control subjects (n = 30) were included
in this study (Table 1). All patients fulfilled the classifi-
cation criteria for T1D. Inclusion criteria were
118 years of age, and normal body mass index (BMI)
according to the Spanish BMI pediatric cohort growth
chart.15 Exclusion criteria were being under immuno-
suppressive or anti-inflammatory treatment, the pres-
ence of other autoimmune diseases, type 2 diabetes,
pregnancy, compromised kidney function, or liver dis-
eases. All patients with T1D were positive for autoanti-
bodies to GAD65 and/or IA-2 at the onset, and were
negative for other autoantibodies (antithyroglobulin,
anti-transglutaminase, and antithyroid peroxidase).
Twenty-two out of the total 52 patients and 14 out of 30





onset (n = 22)
Patients at 6
mo (n = 15)
Patients at
12 mo (n = 14)
Patients at
18 mo (n = 13)
Age (years) 8.1 § 3.6 9.1 § 4.5 9.6 § 4.6 10.1§ 4.6 10.6 § 4.6
Gender (M/F) 3/11 11/11 8/7 8/6 9/5
BMI (kg/m2) 19.4§ 2.4 17.3 § 3.4 18.3§ 3.4 18.3§ 3.6 17.8 § 1.8
HbA1c (%) ND 11.4 § 2.5 7.2 § 1.1 7.7§ 1.04 7.6 § 1.04
HbA1c (mmol/mol) ND 101 § 27.3 55§ 11.6 61§ 11.4 61 § 11.4
Insulin dose (UI/kg/day) ND 0.8 § 0.4 0.53§ 0.2 0.79§ 0.7 0.92 § 0.72
IDDAA1C (%) ND 14.1 § 3.4 9.4 § 1.3 8.9 § 3.5 10.2 § 2.7
All values are mean § SD. No statistical differences were found in age between groups. Statistical differences were found in: insulin dose
(onset vs 6 mo: <, 6 mo vs 12 mo: *, 6 mo vs 18 mo: x, 12 mo vs 18 mo: #); glycated hemoglobin (HbA1c) (onset vs 6 mo: x, onset vs 12 mo: #,
onset vs 18 mo: #); insulin dose-adjusted HbA1c (IDDAA1c) (onset vs 6 mo:<, onset vs 12 mo: < and onset vs 18 mo: x). Statistics: Mann-Whitney
test (*P < 0.05, # P < 0.01, x P < 0.001, < P < 0.0001). BMI, body mass index; HbA1c, glycated hemoglobin; IDDAA1c, insulin dose-adjusted
HbA1c; ND, not determined.
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ELISA experiments, whereas the remaining 30 patients
and 16 control subjects were included in the leukocyte
subsets’ analysis. Patients were considered to be in PR
when they fulfilled one or both of the two accepted crite-
ria. PR was defined as <0.5 UI/kg/d and <7% HbA1c,
or <9 insulin dose-adjusted HbA1c3 (IDDAA1c). All
the participants gave informed consent, and the study
was approved by the Committee on the Ethics of
Research of the Germans Trias i Pujol Research Institute
and Hospital.
ELISA. ELISA method was used to determine plas-
matic concentrations of TGF-b (ThermoFisher Scien-
tific, Waltham, Massachusetts), betatrophin (Wuhan
Eiaab Science, Wuhan, China), and HLA-G (sHLA-G,
Enzo Life Sciences, Farmingdale, New York) in plasma
samples obtained from control subjects and patients
with T1D at the onset and at 6, 12, and 18 months of
progression of the disease. Basic analytical characteris-
tics of the methods were: for betatrophin, detection
range: 785000 pg/mL and sensitivity: >0.051 pg/mL;
for TGF-b, detection range: 81000 pg/mL and sensi-
tivity: 8.6 pg/mL; for sHLA-G, detection range:
3.91125 U/mL, and sensitivity: 0.6 U/mL.
Flow cytometry. For the analysis of cellular subsets,
fresh venous blood samples were collected in ethylene
diamine tetra acetic acid tubes from control subjects
and patients with T1D at the onset and at 6, 12, and 18
months of disease progression. Samples of 1 mL of
whole blood were washed and erythrocytes were lysed
(Lysing Buffer, BD Biosciences, San Jose, California).
A sample of 100 mL was then marked with a panel of
different monoclonal antibodies (BD Biosciences) at
room temperature and protected from light for 20
minutes. The panels, detailed in Table 2, were built as
follows: (1) Th17 lymphocytes panel16: CD4 V450,
CCR6 PE, CCR7 PECy7, and CCR4 AF647; (2) Tregpanel17: CD45 FITC, CD3 V450, CD4 PerCPCy5.5,
CD25 PE, CCR4 PECy7, CD127 AF647, CD45RO
APCH7, HLA-DR V500; (3) T lymphocyte maturation
stages panel16: CD3 V500, CD4 PerCPCy5.5, CD8
APCH7, CD45RA FITC, PTK7 PE, CCR7 PECy7,
CD31 AF647, CD27 BV421; (4) Transitional B cell
panel16: CD19 PerCPCy5.5, CD24 FITC, CD38 PE,
CD27 APC; (5) B lymphocyte maturation stages
panel16: CD3 V450, CD19 V500, CD27 APC, CD21
PE, IgD FITC, IgM PerCPCy5.5; (6) gd T cell panel16:
CD3 PerCP, gd TCR PE, ab TCR FITC, CD8 APCH7,
CD4 V450 and (7) DC/Monocytes/NK17: CD45
AF700, CD3 APCH7, CD19 APCH7, CD14 V450,
CD16 APC, CD11c PECy7, CD123 PerCPCy5.5,
CD56 PE, HLA-DR V500, Slan FITC. At least 10,000
leukocyte events per sample were acquired using
FACS Canto II and LSR Fortessa Flow Cytometers
(BD Biosciences). Corresponding fluorescence minus
one staining was used as control. The gating strategy to
analyze specific leukocyte subsets was based on inter-
national consensus.18 Absolute counts (cells/mL) were
analyzed for all subsets using Perfect Count Micro-
spheres (Cytognos SL, Salamanca, Spain). Data were
analyzed using FACSDiva software (BD Biosciences).
Quantitative RT-PCR. RNA was isolated using RNeasy
Micro Kit (QIAGEN) and reverse-transcribed with a
High Capacity cDNA Reverse Transcription Kit (Ther-
moFisher Scientific). cDNA synthesis was carried out
using random hexamers (0.5 mg/mL, BioTools, Valle
de Tobalina, Madrid, Spain) and reverse transcriptase
Moloney murine Leukemia virus (200 U/mL, Promega,
Madison, Wisconsin). Quantitative RT-PCR assays
were performed on a LightCycler 480 (Roche Diagnos-
tics, Mannheim, Germany) using SYBR Green I Mas-
ter mix (Roche Diagnostics) and specific primers for
HLA-E, HLA-F, TLR3, LYZ, CD36, IL-8, and CXCL1
(Invitrogen, Life Technologies, Gaithersburg,
Table 2. Lymphocyte subsets analyzed in pediatric patients with T1D and their markers according to international
consensus18
Lymphocyte subset Phenotype Reference subset
aTreg CD3+CD4+CD127lowCD25+ CCR4+ CD45RO+HLADR+ mTreg
mTreg CD3+CD4+CD127lowCD25+ CCR4+ CD45RO+ CD3+CD4+
Th17 CD4+ CCR7¡ CCR4+ CCR6+ CD4+
Breg CD19+CD27+CD24hi CD19+
NKreg CD3¡CD19¡CD56+CD14¡CD56brCD16¡ NK cells
Monocytes CD3¡CD19¡CD14+ CD3¡CD19¡
CD14+CD16¡ CD3¡CD19¡CD14+CD16¡ Monocytes
Total CD27+ CD19+CD27+ CD19+
Total B transitional CD19+CD27¡CD24hiCD38+ CD19+
B transitional high CD19+CD27¡CD24hiCD38hi CD19+
B transitional low CD19+CD27¡CD24hiCD38lo CD19+
ab CD3+ ab + ɣd ¡ CD3+
CD3+ DP CD3+CD4+CD8+ CD3+
ɣdCD8+ CD3+ ab ¡ ɣd +CD8+ Total ɣd
CD3+CD4+ CD3+CD4+ Total lymphocytes
Recent thymic emigrants CD3+CD4+CCR7+CD45RA+CD31+PTK7+ CD4+ Naive
CD4+ CM CD3+CD4+CCR7+CD45RA¡CD27+ CD3+CD4+
CD4+ EM CD3+CD4+CCR7¡CD45RA¡ CD3+CD4+
CD4+ EM CD27+ CD3+CD4+CD27+CCR7¡CD45RA¡ CD3+CD4+
CD4+ EMRA CD3+CD4+CCR7¡CD45RA+ CD3+CD4+
CD4+ EMRA CD27+ CD3+CD4+CD27+CCR7¡CD45RA+ CD3+CD4+
CD4+ EMRA CD27¡ CD3+CD4+CD27¡CCR7¡CD45RA+ CD3+CD4+
CD3+CD8+ CD3+CD8+ Total lymphocytes
CD8+Naive CD3+CD8+CCR7+CD45RA+CD27+ CD3+CD8+
CD8+ CM CD3+CD8+CCR7+CD45RA¡CD27+ CD3+CD8+
CD8+ EMRA CD3+CD8+CCR7¡CD45RA+ CD3+CD8+
CD8+ EMRA CD27+ CD3+CD8+CD27+CCR7¡CD45RA+ CD3+CD8+
aTreg, activated regulatory T cell; mTreg, memory regulatory T; Breg, regulatory B; NKreg, regulatory Natural Killer; DP, double positive; CM,
central memory; EM, effector memory; EMRA, CD45+ effector memory.
Translational Research
Volume 210 Villalba et al 11Maryland) (Supplementary Table 1). Relative quantifi-
cation was performed by normalizing the expression of
each gene of interest to that of the housekeeping HPRT
gene following the 2-DDCt method.19
Statistical analysis. The statistical analysis was per-
formed using Prism 7.0. Software (GraphPad software
Inc., San Diego, California). For comparisons of paired
data, a nonparametric Wilcoxon test was used, whereas
a nonparametric Mann-Whitney test was used for com-
parisons of unpaired data. To find statistically significant
correlations between parameters, Spearman’s test was
used. A P value of<0.05 was considered significant.RESULTS
Clinical features of pediatric patients with T1D
throughout the study. No statistical differences between
groups were found in age and BMI; however, they
were found in terms of insulin dose, HbA1c values and
in IDDAA1c values (Table 1).
Circulating TGF-b levels decrease during PR stage. Cir-
culating TGF-b concentration was determined in 10
control subjects and in 22 patients with T1D. Samplesfrom these patients were obtained at 3 checkpoints:
clinical onset (n = 14), 6 months (n = 13), and 12
months (n = 13) of progression of the disease. TGF-b
concentration was significantly decreased at the check-
point of first year when compared to the onset (Fig 1,
A). Then, the possible correlation between this alter-
ation and PR was evaluated. In fact, there is a signifi-
cant decrease in circulating levels of TGF-b in patients
with PR at 6 and 12 months of disease progression (Fig
1, B). In addition, patients at onset were divided in 2
groups (PR or not PR) and TGF-b levels were com-
pared to understand whether those with PR have a less
aggressive T1D onset or rather have a real different
evolution of their diabetes. The results showed that
both groups have similar circulating TGF-b concentra-
tion at the onset, independenlty from T1D progression.
These results show a differential pattern of circulating
TGF-b that discriminates between patients with or
without spontaneous PR. Patients with PR do not have
a less aggressive T1D onset, but a real different evolu-
tion of their diabetes.
Plasmatic concentration of betatrophin is increased in
pediatric patients with T1D. Plasma betatrophin levels (pg/
mL) were significantly increased in patients with T1D at
Fig 1. Plasma levels of TGF-b in pediatric patients with T1D. A, Concentration of TGF-b (pg/mL) in plasma of
control subjects and patients with T1D at different checkpoints (onset and first year of progression). Data pre-
sented as plot box and whiskers (Tukey). (*P < 0.05, Mann-Whitney test). B, Circulating TGF-b concentration
(pg/mL) in plasma of control subjects and patients with T1D at different checkpoints (onset, 6, and 12 months)
grouped with and without spontaneous partial remission (PR) development at 6 months. Data presented as plot
box and whiskers (Tukey). (*P < 0.05, Mann-Whitney test).
Fig 2. Plasma levels of betatrophin in pediatric patients with T1D. A, Circulating betatrophin concentration (pg/
mL) in plasma of control subjects and patients with T1D at different checkpoints (onset, 6, 12, and 18 months of
progression). Data presented as plot box and whiskers (Tukey). Statistical differences were found between
patients and controls (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, Mann-Whitney test). B, Follow-
up of the circulating plasma betatrophin concentration (pg/mL) of the patients with T1D in partial remission
stage. C, Linear regression of the individual values of plasma betatrophin concentration (mg/dL) (Spearman
r = ‒0.3118, P value = 0.0823).
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control subjects, whereas no statistical differences were
found between patients at different disease stages. How-
ever, 12 months after the onset of the disease a trend to
decrease betatrophin concentration was observed
(P = 0.057). No statistical differences were found when
grouping separately patients with and without spontane-
ous PR at 6 months.
To determine betatrophin levels in spontaneous PR, 8
patients with T1D showing PR criteria at 6 months were
selected from the initial group of 22 patients (Table 3)and follow-up was performed during 18 months after
diagnosis. No statistical differences were found in BMI
between groups, although they were observed in insulin
dose, HbA1c and in IDDAA1c. No statistical differen-
ces were found in circulating betatrophin levels in
plasma between the 4 different checkpoints in PR
patients (Fig 2, B), although a tendency for betatrophin
to decrease was observed during disease progression
(P = 0.0823) (Fig 2, C).
The correlation between circulating betatrophin lev-
els with BMI was explored both in general T1D and
Table 3. Clinical data for pediatric patients with T1D at disease onset, and at 6, 12, and 18 mo of disease progression
included in the follow-up measurements of plasma betatrophin
Onset 6 mo 12 mo 18 mo
n 8 8 8 8
Gender (M/F) 5/3 5/3 5/3 5/3
Age (years, mean§ SD) 9.63§ 3.78 10.13 § 3.78 10.63 § 3.78 11.13 § 3.78
BMI (kg/m2) 17.06§ 4.59 18.27 § 2.33 17.57 § 1.2 17.67 § 1.41
Insulin dose (UI/kg/day) 0.72§ 0.58 0.43 § 0.25 0.66§ 0.22 0.75 § 0.31
HbA1c (%) 10.26§ 1.66 6.84 § 0.90 7.86§ 1.10 8.23 § 1.04
HbA1c (mmol/mol) 89§ 18.1 51 § 9.8 62§ 12 66 § 11.4
IDDAA1C (%) 13.15§ 1.93 8.15 § 1.19 10.58 § 1.47 11.33 § 1.05
Data presented as mean§ SD. No statistical differences were found in age between groups. Statistical differences were found in insulin (onset
vs 6 mo: #, 6 mo vs 12 mo: *, 6 mo vs 18 mo: *); glycated hemoglobin (HbA1c) (onset vs 6 mo: #, onset vs 12 mo: *, onset vs 18 mo: *, 6 mo vs
12 mo: #, 12 mo vs 18 mo: #); and in insulin dose-adjusted HbA1c (IDDAA1c) (onset vs 6 mo: x, onset vs 12 mo: * and 6mo vs 18 mo: x). Statistical
differences calculated fromMann-Whitney test (*P< 0.05, # P< 0.01, x P< 0.001,< P< 0.0001). BMI, body mass index; HbA1c, glycated hemo-
globin; IDDAA1c, insulin dose-adjusted HbA1c.
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correlation was found between BMI-betatrophin levels
at the onset stage in T1D patients or in PR patients.
Finally, At 18 months, a statistically significant posi-
tive correlation was found between BMI-betatrophin
levels both in general and in PR patients (P = 0.0047
and 0.0480, respectively).
Immune response-related molecules are altered at the
onset of T1D. Different molecules involved in immune
response were analyzed as potential biomarkers. These
molecules were selected in basis of the altered expres-
sion in the pancreases from patients with T1D.11 One
of these molecules is HLA-G, considered an immuno-
modulatory molecule involved in tolerance and pro-
posed as a pancreatic regulator.20 However, circulating
sHLA-G did not reveal significant differences between
control subjects and patients at different stages
(Fig S1, A). To gain further knowledge within the non-
classical HLA network, the expression of these mole-
cules was also measured in peripheral blood
mononuclear cells (PBMCs) from patients with T1D.
Overexpressed mRNA levels of HLA-E were found in
PBMCs from patients at the onset (Fig S1, B) when
compared to control subjects. In contrast, mRNA levels
of HLA-F were not altered in PBMCs from patients at
the onset when compared to control subjects (Fig S1,
C). The expression of other altered molecules such as
IL-8, TLR3, and CXCL1 was increased in PBMCs
from newly diagnosed patients (Fig S2). A positive
correlation was found between the expression of 2 che-
mokines involved in leukocyte recruitment, IL-8 and
CXCL1 (Fig S3), being moderately positive correlated
in control subjects (R2 = 0.8615) and strongly positive
correlated (R2 = 0.9498) in patients at the onset of
T1D. The expression of other genes, such as CD36 and
LYZ, in PBMCs was not significantly different than
that of control subjects (Fig S2).Regulatory leukocyte subsets are biomarkers of T1D
onset and progression stages. No statistically significant
differences were found in age and BMI between groups
(Table 4). Lymphocyte subsets involved in different
immunoregulation strategies were studied, including
regulatory T cells (Treg), both activated (aTreg) and
memory (mTreg), Th17 cells (which contain a regula-
tory Th17 subset21), regulatory B cells (Breg), and reg-
ulatory Natural Killer cells (NKreg) (Fig 4). No
correlation was found between these subsets (% and
numbers) and the age of the subjects in the different
groups, ie, controls, onset, first year, and second year.
Different percentages of the Treg subset including
both aTreg and mTreg were observed at each T1D
stage (Fig 4, AD). The percentage of aTreg was
increased during the first year of disease in compari-
son to the second year and control subjects (Fig 4,
B), whereas the percentage of mTreg was decreased
only at the onset when compared with control sub-
jects (Fig 4, D). In both cases the concentration was
maintained along the different groups (Fig 4, A and
4, C). The Th17 cell subset, which includes a specific
and minority Th17 regulatory subset, showed an
increased percentage during the first year of progres-
sion when compared to the second year (Fig 4, F).
The corresponding cell concentration was main-
tained during T1D progression, at levels similar to
those found in control subjects (Fig 4, E). The Breg
cell subset was found increased both in concentration
and in percentage during the first year of disease (Fig
4, G and H). Finally, the percentage of NKreg cells
was increased during the second year when com-
pared to the first year of disease (Fig 4, I and J). In
summary, an increase in regulatory T, B and NK sub-
sets was found during T1D progression, reflecting
the attempts to restore tolerance to self during these
early stages.
Fig 3. Correlation of betatrophin levels with BMI in pediatric patients with T1D at different stages of the dis-
ease. Linear regression of circulating plasma betatrophin concentration (pg/mL) vs BMI (kg/m2) in patients with
T1D and control subjects. A, Patients with T1D at the onset (Spearman r = ‒0.00226, P value = 0.9999).
B, Patients who underwent partial remission (PR), at the onset of T1D (Spearman r = ‒0.1429, P value = 0.7520).
C and D, Patients at 6 months of disease progression (Spearman r = 0.634, P value = 0.1705) and those who
underwent PR (Spearman r = 0.3877, P value = 0.1009). E and F, Patients at 12 months of disease progression
(Spearman r = 0.4895, P value = 0.1098), and those who underwent PR (Spearman r = 0.5, P value = 0.2667). G
and H, Patients at 18 months of disease progression (Spearman r = 0.8, P value = 0.0047, **) and PR group
(Spearman r = 0.7857, P value = 0.0480, *). I, Control group (Spearman r = ‒0.07692, P value = 0.8171).
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Table 4. Clinical data for controls, and patients at onset, first and second year of T1D progression included in lymphocyte
subsets analysis
Control Onset 1 y 2 y
N 16 11 12 7
Gender (M/F) 9/7 6/5 3/9 1/6
Age (years, mean§ SD) 8.58 § 4.42 8.69§ 5.16 10.20 § 3.87 10.01 § 2.78
BMI (kg/m2) 19.43 § 1.26 18.24§ 3.10 17.53 § 2.67 18.51 § 2.13
Insulin dose (UI/kg/day) ND 0.69§ 0.27 0.62§ 0.20 0.83 § 0.23
HbA1c (%) ND 8.87§ 1.98 7.86§ 1.17 7.82 § 1.68
HbA1c (mmol/mol) 73§21.58 62 §12.75 62 §18.3
IDDAA1C (%) ND 10.11§ 13.21 8.93§ 11.79 7.09 § 15.25
Data presented as mean§SD. Statistical differences were found in BMI (control subjects vs patients with T1D during the first year: (*)). Statistical
differences calculated using the Mann-Whitney test (*P < 0.05). ND, not determined.
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onset and second year of progression. Alterations in
monocyte counts were found at the early stages of
T1D (Fig 5). Total monocyte count showed a trend to
be lower at the onset of the disease when compared to
control subjects, but at the second year of T1D pro-
gression differences were significant (Fig 5, A and B).
Within this monocyte family, the numbers of classical
monocytes (CD14+CD16‒) confirmed these results
and also showed a decrease at the onset of the disease
(Fig 5, C), but this was not reflected in the percentage
(Fig 5, D). The nonclassical monocyte subset
(CD14+CD16+) showed no statistical differences or
tendencies between the different groups (data not
shown). In summary, the concentration of total mono-
cytes and its major subpopulation, the classical
CD14+CD16‒ monocyte subset, was diminished at the
early stages of diabetes. Since monocytes are precur-
sors of antigen-presenting cells, their decrease in
periphery at the second year of disease progression
suggests an active extravasation to target tissues,
probably to contribute to the chronification of the
autoimmune response.
B lymphocyte subsets are quantitatively altered at the
onset and at early stages of T1D progression. The analysis
of B lymphocytes at different maturation stages, mem-
ory/activation subsets, and B transitional lymphocytes,
revealed quantitative alterations during the first 2 years
of disease progression (Fig 6). The concentration of
CD27+ B cells was increased at the first year of disease
when compared to the onset and to the second year of
disease. However, it was not reflected in the percentage
(Fig 6, A and B). The total B transitional subset also
showed an increase in concentration during the first
year of disease when compared to the second year and
to control subjects, but this alteration was not observed
in the percentage (Fig 6, C and D). Within the B transi-
tional population, alterations were found both in B
transitional high and low subsets (Fig 6, EH), previ-
ously referred as T1 and T2 in the literature. Adecrease in B transitional high subset counts was found
at the second year when compared to control subjects
and to the first year of disease (Fig 6, E), but this
change was not reflected in the percentage (Fig 6, F).
Regarding B transitional low subpopulation, the
amount of these cells was lower at the second year of
disease when compared to the first year (Fig 6, G and
H). This subset includes functional regulatory B cells
and despite its role is not completely understood, their
increase may reflect the attempts to restore self-toler-
ance during T1D early stages.
T lymphocyte subsets are quantitatively altered at the
onset and at early stages of diabetes progression. Be-
cause T cells are the final effector cells in T1D, both ab
and gd T cell populations were screened (Fig 7). The
concentration and percentage of ab T cell subpopula-
tion (Fig 7, A and B) were decreased at the second year
of disease when compared to control and other disease
stages. Among different ab T cells subsets, only double
positive T lymphocytes were decreased in counts at the
second year when compared to the first year of disease
(Fig 7, C) but not in percentage (Fig 7, D). Regarding
the gd CD4+ T cell subset, no differences were found
among different groups (data not shown). The CD8+ gd
subset was decreased in concentration at the first year of
progression when compared to the second year, and the
percentage tended to decrease during disease progres-
sion (Fig 7, E and F). In summary, alterations in total
ab and gd T cell subpopulations were observed during
2 years of T1D progression.
The different T lymphocyte maturation stages were
determined and showed alterations at the onset and at
the different stages of T1D (Figs 810). Only the total
CD3+ CD4+ T lymphocyte population concentration
was found decreased at the onset of T1D when com-
pared to control subjects and the first year of disease
(Fig 8, A and B). Within this population, the central
memory (CM) CD27+ subset revealed alterations both
in concentration and percentage. There was an increase
in concentration in the second year when compared to
Fig 4. Concentration and percentage of regulatory lymphocyte subsets in peripheral blood from pediatric
patients with T1D at different stages of the disease. Concentration (cells/mL) and percentage (%) of A and B, acti-
vated T regulatory cells (aTreg), C and D, memory T regulatory cells (mTreg), E and F, Th17 cells, G and H, B
regulatory cells (Breg), and I and J, Natural Killer regulatory cells (NKreg). White symbols represent control
subjects, whereas black symbols represent patients with T1D at onset (dots), 1 year (squares) and 2 years (trian-
gles) after diagnosis. (*P < 0.05, ***P < 0.001, ****P < 0.0001, Mann-Whitney test).
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Fig 5. Concentration and percentage of monocytes in peripheral blood from pediatric patients with T1D at dif-
ferent stages of the disease. Concentration (cells/mL) and percentage (%) of A and B, total monocytes, and C and
D, its major subset, classical monocytes. White symbols represent control subjects, whereas black symbols rep-
resent patients with T1D at onset (dots), 1 year (squares) and 2 years (triangles) after diagnosis. (*P < 0.05,
Mann-Whitney test).
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increase in percentage at disease onset when compared
to control subjects, with a tendency to decrease with
progression of diabetes until a rate similar to control
group at second year (Fig 8, D). The PTK7+ subpopula-
tion, included in the CD4+ naive subset, revealed an
increase in percentage during the second year of dis-
ease (Fig 8, F).
The CD4+ T lymphocyte effector memory subsets
were analyzed (Fig 9). Total CD4+ effector cells
expressing the marker CD45RA (EMRA) subsets
showed a remarkable decrease in both concentration
(Fig 9, A) and percentage at the onset of the disease (Fig
9, B). Furthermore, this decrease in concentration was
also observed in both CD4+ EMRA subsets: CD27+ (Fig
9, C) and CD27‒ (Fig 9, E), but not in their percentage
(Fig 9, D and Fig 9, F, respectively). In addition, the
CD4+ EM cell subset revealed lower counts at disease
onset when compared to the first year of disease (Fig 9,
G). This is due to alterations in the CD4+ EM CD27+
subset (Fig 9, I). This effect was not reflected in percent-
age (Fig 9, H and Fig 9, J, respectively).Besides the CD4+ population, CM and EM in the
CD8+ subsets were also altered (Fig 10). Total counts
of CD3+ CD8+ T cells were decreased at the onset of
the disease when compared to control subjects, and
normalized after diagnosis (Fig 10, A and B). Regard-
ing the CM subset, a decrease in counts and percent-
age, was observed during the second year of
progression (Fig 10, C and D). The analysis of the
CD8+ na€ıve cells subset showed a decrease in cell
number at the onset and during the first year of disease
(Fig 10, E), in agreement with the data of CD3+ CD8+
population (Fig 10, A). Moreover, a decrease in
EMRA CD8+ T cell counts (Fig 10, G) was observed,
but not in percentage (Fig 10, H). This decrease in con-
centration was observed at T1D onset in the EMRA
CD27+ subset (Fig 10, I), whereas in percentage, a
decrease was found at the first year of the disease (Fig
10, J). In summary, alterations in the CM and EM line-
ages of T lymphocytes and their maturation stages
have been detected at early T1D progression. All these
cell subsets are commonly found in the spleen and in
the lymph nodes, and the decrease in peripheral blood
Fig 6. Concentration and percentage of B lymphocytes in peripheral blood from pediatric patients with T1D at
different stages of the disease. Concentration (cells/mL) and percentage (%) of A and B, total CD27+ peripheral
blood mononuclear cells (PBMCs), C and D, total B transitional lymphocytes, E and F, B transitional high, and
G and H, B transitional low. White symbols represent control subjects, whereas black symbols represent patients
with T1D at onset (dots), 1 year (squares) and 2 years (triangles) after diagnosis. (*P < 0.05, **P < 0.01, Mann-
Whitney test).
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Fig 7. Concentration and percentage of ab and gd T lymphocytes in peripheral blood from pediatric patients
with T1D at different stages of the disease. Concentration (cells/mL) and percentage (%) of A and B, total ab, C
and D, its subset CD3+ double positive (DP), and E and F, gd CD8+. White symbols represent control subjects,
whereas black symbols represent patients with T1D at onset (dots), 1 year (squares) and 2 years (triangles) after
diagnosis. (*P < 0.05, Mann-Whitney test).
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CD8+ T cell subsets at the onset could reflect the need
for a compensatory mechanism, due to an active migra-
tion to target tissue.DISCUSSION
It is known that the lack of biomarkers of T1D stages
hinders the proper stratification patients, the predictionof secondary complications, and the discovery of optimal
checkpoints for potential therapies. Metabolic parame-
ters are currently the most reliable biomarkers, and dur-
ing disease progression, C-peptide levels are considered
to reflect residual insulin storage. Although this is a good
biomarker for endogenous insulin production and secre-
tion, the sensitivity of the technique prevents the assess-
ment of low values22 and most pediatric patients show
undetectable C-peptide levels at disease onset.6 Thus,
novel biomarkers for stratifying subjects and for
Fig 8. Concentration and percentage of CD4+ T lymphocyte subsets. Concentration (cells/mL) and percentage
(%) of A and B, total CD3+CD4+, C and D, CD4+ CM CD27+ and E and F, its major subset PTK7+. White sym-
bols represent control subjects, whereas black symbols represent patients with T1D at onset (dots), 1 year
(squares) and 2 years (triangles) after diagnosis (*P < 0.05, Mann-Whitney test).
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screening of candidate biomarkers in pediatric patients
with T1D, with special interest in the early stages.
There are many and diverse immune biomarkers of
T1D.23 In this pilot study, aimed at determining dif-
ferential molecular and cell patterns in children diag-
nosed with T1D in our geographic area, potential
candidates have been considered. Betatrophin, a
promising biomarker in long-standing adult patients
with T1D,8 showed a triplicated concentration inplasma at the onset of pediatric T1D. Furthermore,
those increased levels remain steady during the early
progression of the disease, including the PR stage.
Thus, circulating betatrophin levels in plasma do not
distinguish PR stage. Our results of the correlation
between a metabolic parameter such as BMI and cir-
culating betatrophin levels are in keeping with those
described in T1D8 and T2D24 that suggest that hyper-
glycemia may be the pivotal point for betatrophin
upregulation in diabetes.
Fig 9. Concentration and percentage values of CD4+ and its effector memory (EM) subset, included in the T
lymphocytes maturation stages. Values in concentration (cells/mL) and percentage (%) of A and B, total EMRA
CD4+, C and D, CD4+ EMRA CD27+, E and F, CD4+ EMRA CD27‒, G and H, total CD4+ EM, and I and J,
CD4+ EM CD27+. White symbols represent control subjects, whereas black symbols represent patients with
T1D at onset (dots), 1 year (squares) and 2 years (triangles) after diagnosis (*P < 0.05, **P < 0.01, ****P <
0.0001, Mann-Whitney test).
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Fig 10. Concentration and percentage values of CD8+ lymphocytes and their subsets, included in the T lympho-
cytes maturation stages. Values in concentration (cells/mL) and percentage (%) of A and B, total CD3+CD8+, C
and D, CD8+ CM CD27+, E and F, CD8+ Na€ıve CD27, G and H, total CD8+ EMRA, and I and J, its subset
CD8+ EMRA CD27+. White symbols represent control subjects, whereas black symbols represent patients with
T1D at onset (dots), 1 year (squares) and 2 years (triangles) after diagnosis (*P < 0.05, **P < 0.01, ***P <
0.001, Mann-Whitney test).
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Table 5. Summary of candidate biomarkers altered during pediatric T1D early progression
Candidate biomarker Source Stage Outcome
Betatrophin Plasma Onset, 6, 12, and 18 mo of progression Increased
TGF-b Plasma Partial remission Decreased
aTreg (%) Blood First year of progression Increased
Breg (% and counts) Blood First year of progression Increased
NKreg (%) Blood Second year of progression Increased
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Volume 210 Villalba et al 23Then, the potential of other immune mediators
whose expression was strongly altered in the pan-
creases from patients with T1D11 was analyzed. Here
we demonstrate for the first time a decrease in circu-
lating TGF-b during PR when compared to the onset.
This candidate biomarker for PR distinguishes pediat-
ric patients until 1 year after diagnosis. Low TGF-b
levels in PR could reflect the transient recovery of
self-tolerance proposed at this stage.1 In fact, TGF-b
is increased in patients at the onset of T1D10 reflect-
ing a response to autoimmunity activation and corre-
lating with the fact that hyperglycemia stimulates
TGF-b expression.25 Because many cells can secrete
TGF-b, a deeper understanding of the mechanisms
involved in the decrease of plasma concentration dur-
ing PR is needed. In this stage, the remaining b-cells
are still able to produce enough insulin and, in some
cases, transient insulin-independence can be
achieved. The identification of reliable biomarkers
would allow for the identification and monitorization
of PR. Because there are no differences in TGF-b lev-
els when comparing patients at PR and non PR stages
at 6 and 12 months of evolution of the disease, at
present it would be useful for the monitoring of PR
for each particular patient.
Additionally, lymphocyte cell subsets have been
used as biomarkers for several immune mediated dis-
eases. One of the main advantages of using them is the
amount of given information due to the multiple
parameters that can be analyzed in the sample, and its
ease of tracking during disease progression. Lympho-
cyte regulatory subsets have been partially character-
ized in T1D. Since they are crucial in self-tolerance
and show phenotypic, functional and migration altera-
tions in autoimmunity,26,27 this study aimed at deter-
mining the changes in regulatory leukocyte subsets
during the first 2 years of T1D in children. Alterations
were found in all regulatory leukocyte subsets both in
concentration and percentage, reflecting a robust sig-
nificance. Moreover, the alterations observed in one
variable can be due to compensatory mechanisms
undergone by other cell lineage subsets to accommo-
date the first change. Since lymphocyte subsets can
only be determined in peripheral blood at a time,
peripheral subsets are tightly regulated by theirgeneration in primary lymphoid organs and by their
migration to the target tissue, ie, the pancreas in T1D.
The decrease of the percentage of mTreg at the onset
of the disease in children is accompanied by a strong
increase in aTreg at the first year. Since Tregs are cru-
cial in self-tolerance, these data reflect the autoimmune
attack at T1D onset as mTregs are reduced. The
increase in aTregs during the first year of disease,
which is also when the classical appearance of PR
occurs, may reveal the attempts to restore self-toler-
ance. In this sense, a mathematical model explains that
T1D onset is the consequence of an increase in effector
T lymphocytes over Treg and that the PR stage may be
due to an inversion in the frequencies of these sub-
sets.28 As for Breg and NKreg cell subsets, their role in
T1D is not completely understood. This is the first
report showing an increase of Breg and NKreg in early
stages of pediatric T1D. Future studies may provide
insight into the role of these cells in PR and T1D.
We are well aware of the limitations of this study.
Despite a relatively small sample size, the P value of
the here proposed biomarkers  betatrophin, TGF-b
and regulatory T, B, and NK subsets  determines sta-
tistical differences. Furthermore, these candidates were
selected from previous data and in basis of their biolog-
ical effect. Future analysis of “big data” obtained from
an independent cohort would be beneficial for both val-
idation of these candidate biomarkers and for the
screening of new ones. Nevertheless, the strength of
the study is the identification of immunologic altera-
tions in early stages of the disease, with special interest
in the PR, an unexplored  and often undetected 
phase of T1D. In our cohort PR was evident at
6 months after diabetes onset. Thus, we plan to include
this time checkpoint for all patients and variables to be
investigated in future studies.
Overall, the results (summarized in Table 5) reveal
the characterization of the changes in these parameters
during the different early stages of T1D in children 
betatrophin, TGF-b and regulatory T, B and NK sub-
sets  that could be used in clinical practice to charac-
terize the progression of T1D. Moreover, and because
PR may be an ideal stage for immunointervention,
these candidate biomarkers can be considered for clini-
cal trials. This study constitutes an open door, not only
Translational Research
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stages of T1D, but also to stratify the patients for future
therapeutic strategies.ACKNOWLEDGMENTS
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